树突状细胞(DC)是目前发现的功能最强的抗原提呈细胞(APC),近年来对DC的研究成为热点。本文对DC应用于髓性白血病尤其是具有明确白血病抗原的白血病特异性免疫治疗方面的研究进展进行综述。

Objective: To study the vaccine potency of gene-modified tumor cells, we have constructed IL-12, H7-1 and GM-CSF express vector using retrovirus. Methods: It was transfected into EL-4 thymic lylmphoma cells respectively and the effect of gene transduction on anti-tumor immunity were investigated. Results: The tumorigenicity of EL-4/IL-12 transfectant in C57BI/6 syn- ergistical mice was decreased significantly after implanted with EL-4/IL-12 transfectant compaired with EL-4/Wt or EL-4/Neo groups (P<0. 01). The systemic protective immunity was induced against the challenge with EL-4/Wt (in 10/15 mice) after the rejection of EL-4/IL-12 in the experiment, a stronger CTL activity against EL-4/Wt cells and a weak killer activity against syn- geneic Lewis Lung Carcinoma cells were obtained in 51Cr release assay. In vivo depletion analysis suggested that the decreased tumorigenicity mainly depended on CD4 , CD8 and NK cells. Therapeutic vaccines with EL-4/IL-12 cells could retard the growth to estabished EL-4/Wt tumors significantly compared with those of EL-4/Neo(P < 0 .005 ), combination of therapeutic vaccines of EL-4/IL-12 and EL-4/B7-1 result in the enhanced the therapeutic effect of each single transficants (P < 0 .005) in this experimental model. Conclution: These studies suggested that immunogene treatment using IL-12 is effective in hematopoi- etic malignancy, and combination of IL-12 with B7-1 have a aplication value in human cancer treatment in the near future.

R730.51

* 本文受长海医院123人才基金(9936104)资助